|
1
|
Colombo N, Parma G, Zanagnolo V and
Insinga A: Management of ovarian stromal cell tumors. J Clin Oncol.
25:2944–2951. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Young RH and Scully RE: Endocrine tumors
of the ovary. Curr Top Pathol. 85:113–164. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fox H, Agrawal K and Langley FA: A
clinicopathologic study of 92 cases of granulosa cell tumor of the
ovary with special reference to the factors influencing prognosis.
Cancer. 35:231–241. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fuller PJ, Chu S, Fikret S and Burger HG:
Molecular pathogenesis of granulosa cell tumours. Mol Cell
Endocrinol. 191:89–96. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jamieson S and Fuller PJ: Management of
granulosa cell tumour of the ovary. Curr Opin Oncol. 20:560–564.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chu S, Rushdi S, Zumpe ET, Mamers P, Healy
DL, Jobling T, Burger HG and Fuller PJ: FSH-regulated gene
expression profiles in ovarian tumours and normal ovaries. Mol Hum
Reprod. 8:426–433. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fuller PJ and Chu S: Signaling pathways in
the molecular pathogenesis of ovarian granulosa cell tumours.
Trends Endocrinol Metab. 15:122–128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Anttonen M, Unkila-Kallio L, Leminen A,
Butzow R and Heikinheimo M: High GATA-4 expression associates with
aggressive behavior, whereas low anti-Müllerian hormone expression
associates with growth potential of ovarian granulosa cell tumors.
J Clin Endocrinol Metab. 90:6529–6235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shah SP, Köbel M, Senz J, Morin RD, Clarke
BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, et al:
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J
Med. 360:2719–2729. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schrader KA, Gorbatcheva B, Senz J,
Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke
SL, Leung P, Brenton JD, et al: The specificity of the FOXL2
c.402C>G somatic mutation: A survey of solid tumors. PLoS One.
4:e79882009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim MS, Hur SY, Yoo NJ and Lee SH:
Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of
ovary and other human cancers. J Pathol. 221:147–152. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berek JS, Crum C and Friedlander M: Cancer
of the ovary, fallopian tube, and peritoneum. Int J Gynaecol
Obstet. 131(Suppl 2): S111–S122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zaloudek CJ, Mooney EE, Staats PN and
Young RH: Tumours of the ovary and peritoneum. World Health
Organization Classification of Tumours: Pathology and Genetics of
Tumours of the Breast and Female Genital Organs. Kurman R,
Carcangiu ML, Herrington CS and Young RH: IARC Press; Lyon: pp.
1462014
|
|
14
|
Rosario R, Wilson M, Cheng WT, Payne K,
Cohen PA, Fong P and Shelling AN: Adult granulosa cell tumours
(GCT): Clinicopathological outcomes including FOXL2 mutational
status and expression. Gynecol Oncol. 131:325–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
D'Angelo E, Mozos A, Nakayama D, Espinosa
I, Catasus L, Muñoz J and Prat J: Prognostic significance of FOXL2
mutation and mRNA expression in adult and juvenile granulosa cell
tumors of the ovary. Mod Pathol. 24:1360–1367. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kommoss S, Gilks CB, Penzel R, Herpel E,
Mackenzie R, Huntsman D, Schirmacher P, Anglesio M, Schmidt D and
Kommoss F: A current perspective on the pathological assessment of
FOXL2 in adult-type granulosa cell tumours of the ovary.
Histopathology. 64:380–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uhlenhaut NH, Jakob S, Anlag K,
Eisenberger T, Sekido R, Kress J, Treier AC, Klugmann C, Klasen C,
Holter NI, et al: Somatic sex reprogramming of adult ovaries to
testes by FOXL2 ablation. Cell. 139:1130–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cocquet J, De Baere E, Gareil M, Pannetier
M, Xia X, Fellous M and Veitia RA: Structure, evolution and
expression of the FOXL2 transcription unit. Cytogenet Genome Res.
101:206–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cocquet J, Pailhoux E, Jaubert F, Servel
N, Xia X, Pannetier M, De Baere E, Messiaen L, Cotinot C, Fellous M
and Veitia RA: Evolution and expression of FOXL2. J Med Genet.
39:916–921. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Crisponi L, Deiana M, Loi A, Chiappe F,
Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, et al:
The putative forkhead transcription factor FOXL2 is mutated in
blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet.
27:159–166. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duffin K, Bayne RA, Childs AJ, Collins C
and Anderson RA: The forkhead transcription factor FOXL2 is
expressed in somatic cells of the human ovary prior to follicle
formation. Mol Hum Reprod. 15:771–777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Crisponi L, Uda M, Deiana M, Loi A,
Nagaraja R, Chiappe F, Schlessinger D, Cao A and Pilia G: FOXL2
inactivation by a translocation 171 kb away: Analysis of 500 kb of
chromosome 3 for candidate long-range regulatory sequences.
Genomics. 83:757–764. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beysen D, Vandesompele J, Messiaen L, De
Paepe A and De Baere E: The human FOXL2 mutation database. Hum
Mutat. 24:189–193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harris SE, Chand AL, Winship IM, Gersak K,
Aittomäki K and Shelling AN: Identification of novel mutations in
FOXL2 associated with premature ovarian failure. Mol Hum Reprod.
8:729–733. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim T, Sung CO, Song SY, Bae DS and Choi
YL: FOXL2 mutation in granulosa-cell tumours of the ovary.
Histopathology. 56:408–410. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jamieson S, Butzow R, Andersson N,
Alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ and Anttonen
M: The FOXL2 C134 W mutation is characteristic of adult granulosa
cell tumors of the ovary. Mod Pathol. 23:1477–1485. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Al-Agha OM, Huwait HF, Chow C, Yang W,
Senz J, Kalloger SE, Huntsman DG, Young RH and Gilks CB: FOXL2 is a
sensitive and specific marker for sex cord-stromal tumors of the
ovary. Am J Surg Pathol. 35:484–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Benayoun BA, Caburet S, Dipietromaria A,
Georges A, D'Haene B, Pandaranayaka PJ, L'Hôte D, Todeschini AL,
Krishnaswamy S, Fellous M, et al: Functional exploration of the
adult ovarian granulosa cell tumor-associated somatic FOXL2
mutation p.Cys134Trp (c.402C>G). PLoS One. 5:e87892010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kommoss S, Anglesio MS, Mackenzie R, Yang
W, Senz J, Ho J, Bell L, Lee S, Lorette J, Huntsman DG and Blake
Gilks C: FOXL2 molecular testing in ovarian neoplasms: Diagnostic
approach and procedural guidelines. Mod Pathol. 26:860–867. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benayoun BA, Anttonen M, L'Hôte D,
Bailly-Bechet M, Andersson N, Heikinheimo M and Veitia RA: Adult
ovarian granulosa cell tumor transcriptomics: Prevalence of FOXL2
target genes misregulation gives insights into the pathogenic
mechanism of the p.Cys134Trp somatic mutation. Oncogene.
32:2739–2746. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosario R, Araki H, Print CG and Shelling
AN: The transcriptional targets of mutant FOXL2 in granulosa cell
tumours. PLoS One. 7:e462702012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soh J, Okumura N, Lockwood WW, Yamamoto H,
Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et
al: Oncogene mutations, copy number gains and mutant allele
specific imbalance (MASI) frequently occur together in tumor cells.
PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Improta G, Pelosi G, Tamborini E, Donia M,
Santinami M, de Braud F and Fraggetta F: Biological insights into
BRAFV600 mutations in melanoma patient: Not mere therapeutic
targets. Oncoimmunology. 2:e255942013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Geiersbach KB, Jarboe EA, Jahromi MS,
Baker CL, Paxton CN, Tripp SR and Schiffman JD: FOXL2 mutation and
large-scale genomic imbalances in adult granulosa cell tumors of
the ovary. Cancer Genet. 204:596–602. 2011. View Article : Google Scholar : PubMed/NCBI
|
